News & Events about Aura Biosciences Inc.
Aura Biosciences (NASDAQ:AURA Get Rating) had its price objective trimmed by JMP Securities from $30.00 to $25.00 in a research note published on Thursday morning, The Fly reports. The firm currently has an outperform rating on the stock. Aura Biosciences Trading Up 1.4 % Shares of NASDAQ AURA ...
Aura Biosciences, Inc. (Aura) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a...
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011), for the...
Market News Video
2years ago
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So lets look at two noteworthy recent insider buys...
Aura Biosciences, Inc. (NASDAQ:AURA Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 333,000 shares, a growth of 73.3% from the March 15th total of 192,200 shares. Based on an average trading volume of 28,900 ...